Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Organogenesis stock

Learn how to easily invest in Organogenesis stock.

Organogenesis Holdings Inc
- $0.32 ( - 4.19%)

Organogenesis Holdings Inc is a drug manufacturers-specialty & generic business based in the US. Organogenesis shares (ORGO) are listed on the NASDAQ and all prices are listed in US Dollars. Organogenesis employs 910 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Organogenesis

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ORGO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Organogenesis stock price (NASDAQ: ORGO)

Use our graph to track the performance of ORGO stocks over time.

Organogenesis shares at a glance

Information last updated 2022-01-17.
Latest market close$7.63
52-week range$7.64 - $24.34
50-day moving average $9.78
200-day moving average $14.57
Wall St. target price$24.00
PE ratio 18.1857
Dividend yield N/A (0%)
Earnings per share (TTM) $0.46

Buy Organogenesis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Organogenesis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Organogenesis price performance over time

Historical closes compared with the close of $7.63 from 2022-01-20

1 week (2022-01-14) -9.38%
1 month (2021-12-22) -23.93%
3 months (2021-10-22) -28.02%
6 months (2021-07-22) -48.79%
1 year (2021-01-22) -27.81%
2 years (2020-01-22) 52.30%
3 years (2019-01-22) 21.47
5 years (2017-01-20) 9.88

Is Organogenesis stock undervalued or overvalued?

Valuing Organogenesis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Organogenesis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Organogenesis's P/E ratio

Organogenesis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Organogenesis shares trade at around 18x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Organogenesis's EBITDA

Organogenesis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $85 million.

The EBITDA is a measure of a Organogenesis's overall financial performance and is widely used to measure a its profitability.

Organogenesis financials

Revenue TTM $446.3 million
Operating margin TTM 16.94%
Gross profit TTM $251 million
Return on assets TTM 15.32%
Return on equity TTM 48.88%
Profit margin 13.95%
Book value $1.47
Market capitalisation $1.1 billion

TTM: trailing 12 months

Organogenesis share dividends

We're not expecting Organogenesis to pay a dividend over the next 12 months.

Organogenesis share price volatility

Over the last 12 months, Organogenesis's shares have ranged in value from as little as $7.64 up to $24.336. A popular way to gauge a stock's volatility is its "beta".

ORGO.US volatility(beta: 1.55)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Organogenesis's is 1.5501. This would suggest that Organogenesis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Organogenesis overview

Organogenesis Holdings Inc. , a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds. Its surgical and sports medicine products comprise NuCel, a surgically implanted allograft used primarily in spinal and orthopedic surgical applications; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor, a chorionic membrane wound covering; TransCyte, a bioengineered tissue for the treatment of partial thickness burns; and Gintuit, a bioengineered bi-layered living cellular tissue for the treatment of mucogingival conditions in adults. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.

Frequently asked questions

What percentage of Organogenesis is owned by insiders or institutions?
Currently 63.209% of Organogenesis shares are held by insiders and 42.418% by institutions.
How many people work for Organogenesis?
Latest data suggests 910 work at Organogenesis.
When does the fiscal year end for Organogenesis?
Organogenesis's fiscal year ends in December.
Where is Organogenesis based?
Organogenesis's address is: 85 Dan Road, Canton, MA, United States, 02021
What is Organogenesis's ISIN number?
Organogenesis's international securities identification number is: US68621F1021
What is Organogenesis's CUSIP number?
Organogenesis's Committee on Uniform Securities Identification Procedures number is: 68621F102

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site